Infographic: Assessing the benefits and costs of risk-stratified surveillance for patients with metabolic-associated fatty liver disease
About one in three Australians have metabolic-associated fatty liver disease (MAFLD) - a liver disease common in people who are overweight, obese, or have other metabolic conditions.
Targeted routine liver surveillance can reduce the likelihood of hepatocellular carcinoma (HCC) death by 27% in patients while improving cost-effectiveness to $16,000 per life-year saved and reducing resource burden.
Reports 
Videos